Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine symbols : Tbio save search
mRNA Platform Global Market Report 2022: A Game Changer for Flu Viruses Eluding Conventional Vaccine Efforts
Published: 2022-07-15 (Crawled : 14:00) - prnewswire.com
SGMO | $0.5552 2.17% 2.13% 1.7M
|
Health Technology
|
| O: 1.98%
H: 0.0%
C: -1.94%
MRNA S | $103.86 -1.22% -1.23% 2.2M
|
Health Technology
|
| O: 0.68%
H: 3.73%
C: 3.67%
global report vaccine mrna platform market
Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development
Published: 2021-08-03 (Crawled : 06:00) - globenewswire.com
MS 3 d | $86.99 0.93% -0.26% 9.5M
|
Finance
|
| O: 0.54%
H: 0.29%
C: -0.16%
TBIO | $0.3937 -3.98% -4.14% 32K
|
Health Technology
|
| O: 29.16%
H: 0.21%
C: 0.05%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.31%
H: 0.22%
C: 0.12%
vaccine technology
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
Published: 2021-06-22 (Crawled : 06:00) - globenewswire.com
TBIO | $0.3937 -3.98% -4.14% 32K
|
Health Technology
|
| O: 0.0%
H: 10.57%
C: 10.25%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.57%
H: 0.25%
C: -0.04%
phase 1 vaccine influenza trial phase 2 phase 3
Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program
Published: 2021-06-07 (Crawled : 12:00) - globenewswire.com
TBIO | $0.3937 -3.98% -4.14% 32K
|
Health Technology
|
| O: 0.48%
H: 4.45%
C: 2.41%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.32%
H: 0.85%
C: -0.06%
vaccine influenza milestone
Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines
Published: 2021-04-19 (Crawled : 12:00) - globenewswire.com
TBIO | $0.3937 -3.98% -4.14% 32K
|
Health Technology
|
| O: 0.37%
H: 2.17%
C: 1.69%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.05%
H: 0.15%
C: -0.04%
covid results vaccine preclinical pre-clinical
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
Published: 2021-03-12 (Crawled : 07:00) - globenewswire.com
TBIO | $0.3937 -3.98% -4.14% 32K
|
Health Technology
|
| O: 4.53%
H: 0.91%
C: -2.26%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.48%
C: 0.42%
covid phase 1 vaccine trial phase 3 phase 2 covid-19
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.